**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Fabien HYAFIL, Georges-Pompidou European Hospital, DMU IMAGINA, Assistance Publique-Hôpitaux de Paris, University of Paris Cité, Department of Nuclear Medicine, 75015 Paris, France

**Main Body of the Abstract**
Introduction: Transthyretin cardiac amyloidosis (ATTR-CM) diagnosis is complex, including numerous examinations and medical specialists. DIAM-ATTR survey aimed to obtain a snapshot of the current ATTR-CM diagnostic pathway in France via an electronic survey. Almost 70% of the 20.067 French healthcare professionals (including 775 nuclear medicine physicians (NMp)), potentially implicated in ATTR-CM diagnosis were contacted. A section was dedicated to NMp to assess their current practices for cardiac scintigraphy with bone radiotracers and to evaluate access to cardiac bone scintigraphy (CBS).
Results: 1264 physicians from 7 different specialties including 148 NMp completed the survey. NMp worked in academic hospitals (35%), general hospitals (31%), or private practices (26%). 20% performed early acquisitions and 72% used SPECT acquisition. Perugini grading scale was carried out by 93% of the NMp but only 31% and 5% systematically performed heart/whole body or heart/mediastinum signal quantification, respectively. The overall median (Q1;Q3) delay to obtain results for cardiac bone scan was estimated at 2 weeks (2;4) compared to 4 (3;8) for cardiac MRI, and 2 (2 ; 4) weeks for a biopsy. Among all physicians, 68% rarely or never faced difficulties for CBS. The main difficulties encountered were: appointment delay (60%), geographical distance (17%), interpretation (12%).
Conclusions: Access to CBS for French patients with a suspicion of ATTR-CM and quality of reports appear excellent showing good adherence to the recommended acquisition protocols and the widespread use of the Perugini grading scale. However, quantitative measurements were less performed underscoring room for improvement.
Funding: Sponsored by Carely, funding by Pfizer.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Fabien HYAFIL, Georges-Pompidou European Hospital, DMU IMAGINA, Assistance Publique-Hôpitaux de Paris, University of Paris Cité, Department of Nuclear Medicine, 75015 Paris, France

**Main Body of the Abstract**
**Introduction:** Transthyretin cardiac amyloidosis (ATTR-CM) diagnosis is complex, including numerous examinations and medical specialists. DIAM-ATTR survey aimed to obtain a snapshot of the current ATTR-CM diagnostic pathway in France via an electronic survey. Almost 70% of the 20.067 French healthcare professionals (including 775 nuclear medicine physicians (NMp)), potentially implicated in ATTR-CM diagnosis were contacted. A section was dedicated to NMp to assess their current practices for cardiac scintigraphy with bone radiotracers and to evaluate access to cardiac bone scintigraphy (CBS).
**Results:** 1264 physicians from 7 different specialties including 148 NMp completed the survey. NMp worked in academic hospitals (35%), general hospitals (31%), or private practices (26%). 20% performed early acquisitions and 72% used SPECT acquisition. Perugini grading scale was carried out by 93% of the NMp but only 31% and 5% systematically performed heart/whole body or heart/mediastinum signal quantification, respectively. The overall median (Q1;Q3) delay to obtain results for cardiac bone scan was estimated at 2 weeks (2;4) compared to 4 (3;8) for cardiac MRI, and 2 (2 ; 4) weeks for a biopsy. Among all physicians, 68% rarely or never faced difficulties for CBS. The main difficulties encountered were: appointment delay (60%), geographical distance (17%), interpretation (12%).
**Conclusions:** Access to CBS for French patients with a suspicion of ATTR-CM and quality of reports appear excellent showing good adherence to the recommended acquisition protocols and the widespread use of the Perugini grading scale. However, quantitative measurements were less performed underscoring room for improvement.
**Funding:** Sponsored by Carely, funding by Pfizer.



Current practices and access to cardiac bone scans for the detection of transthyretin cardiac amyloidosis based on the results of a large national electronic survey PB57 (#109)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.